Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences &Peking Union Medical College, Nanjing, China.
Department of Dermatology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
BMC Infect Dis. 2024 Jan 18;24(1):104. doi: 10.1186/s12879-023-08938-x.
With the widespread use of antibiotics, antimicrobial resistance in Neisseria gonorrhoeae is worsening. The objective of this study was to evaluate the efficacy changes of seven antibiotics in the treatment of N. gonorrhoeae by using Monte Carlo simulation combined with pharmacokinetics/pharmacodynamics/ (PK/PD).
The minimum inhibitory concentration (MIC) of antibiotics against clinical isolates from 2013 to 2020 in Nanjing, China, was determined by agar dilution method. The probability of target attainment (PTA) was estimated at each MIC value and the cumulative fraction of response (CFR) was calculated to evaluate the efficacy of these regimens.
All dosage regimens of seven antibiotics achieved PTAs ≥ 90% for MIC ≤ 0.06 µg/ml. But when the MIC was increased to 1 µg/ml, PTAs at each MIC value exceeded 90% only for ceftriaxone 1,000 mg and 2,000 mg, zoliflodacin 2,000 mg and 3,000 mg. Among them, the CFR values of each dosing regimen against N. gonorrhoeae only for ceftriaxone, cefixime and zoliflodacin were ≥ 90% in Nanjing from 2013 to 2020.
Cephalosporins are still the first-line drugs in the treatment of gonorrhea. However, the elevated MIC values of cephalosporins can lead to decline in clinical efficacy of the conventional dose regimens, and increasing the dose of ceftriaxone to 1,000 mg-2,000 mg may improve the efficacy. In addition, zoliflodacin is possible to be a potential therapeutic agent in the future.
随着抗生素的广泛使用,淋病奈瑟菌的抗菌药物耐药性日益恶化。本研究旨在通过蒙特卡罗模拟结合药代动力学/药效学(PK/PD)评估七种抗生素治疗淋病奈瑟菌的疗效变化。
采用琼脂稀释法测定中国南京 2013 年至 2020 年临床分离株的抗生素最低抑菌浓度(MIC)。在每个 MIC 值下估算目标达标概率(PTA),并计算累积反应分数(CFR)以评估这些方案的疗效。
七种抗生素的所有剂量方案在 MIC≤0.06μg/ml 时 PTA≥90%。但当 MIC 增加至 1μg/ml 时,只有头孢曲松 1000mg 和 2000mg、唑氟沙星 2000mg 和 3000mg 各 MIC 值的 PTA 超过 90%。其中,头孢曲松、头孢克肟和唑氟沙星在南京 2013 年至 2020 年的每个给药方案对淋病奈瑟菌的 CFR 值均≥90%。
头孢菌素仍然是治疗淋病的一线药物。然而,头孢菌素 MIC 值升高可能导致常规剂量方案的临床疗效下降,增加头孢曲松剂量至 1000mg-2000mg 可能提高疗效。此外,唑氟沙星可能成为未来有潜力的治疗药物。